Related Experiment Video
Updated: Sep 11, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
CROI 2025: Metabolic and Other Complications of HIV Infection
1Johns Hopkins University, Baltimore, MD, USA.
Insights
New research from the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) highlights aging comorbidities in people with HIV (PWH). Studies focused on cardiovascular health, aging markers, and treatment impacts, offering crucial clinical insights.
Area of Science:
- Infectious Diseases
- Gerontology
- Cardiology
- Virology
Background:
- Aging-related comorbid conditions significantly impact health, quality of life, and survival in people with HIV (PWH).
- The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) presented key findings on comorbidities in PWH.
Purpose of the Study:
- To review and highlight clinically impactful abstracts from CROI 2025 concerning aging comorbidities in PWH.
- To synthesize recent research on cardiovascular diseases, biologic aging markers, and treatment effects in PWH.
Main Methods:
- Review of abstracts presented at CROI 2025.
- Analysis of studies focusing on cardiovascular diseases (atherosclerosis, heart failure), epigenetic aging markers, and treatment interventions.
- Inclusion of data from REPRIEVE trial ancillary analyses and global studies.
Main Results:
- Cardiovascular diseases remain a major focus, with ongoing research from REPRIEVE and global cohorts.
- Epigenetic markers of aging and the impact of treatments like glucagon-like peptide-1 receptor agonists were explored.
- Cytomegalovirus suppression demonstrated benefits in reducing immune activation, inflammation, and improving physical function.
- Switching to integrase strand transfer inhibitors was linked to increased diabetes and hypertension risk, independent of weight gain.
Conclusions:
- CROI 2025 underscored the complex interplay between aging, comorbidities, and HIV management.
- Emerging research highlights potential therapeutic targets and risks associated with specific HIV treatments.
- Further investigation into cardiovascular health and aging biomarkers is crucial for improving long-term outcomes in PWH.
Abstract:
Aging-related comorbid conditions have major effects on health, quality of life, and survival in people with HIV (PWH). The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) featured numerous studies about comorbid diseases in PWH. Cardiovascular diseases, including atherosclerosis and heart failure were important topics at the CROI, with ancillary analyses from REPRIEVE (the Randomized Trial to Prevent Vascular Events in HIV) and studies from lower- and middle-income countries. Numerous studies examined epigenetic markers of biologic aging in PWH and the effects of treatments, including glucagon-like peptide-1 receptor agonists. In a clinical trial, cytomegalovirus suppression was shown to decrease immune activation and systemic inflammation, as well as improve physical function. Large epidemiologic studies examining the effect of switching to integrase strand transfer inhibitors showed an increased risk of diabetes and hypertension, which was independent of weight gain. This review focuses on the abstracts presented at CROI 2025 in these areas, highlighting those with the most clinical impact.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Diabetes: Symptoms, Diagnosis, and Complications
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Retrovirus Life Cycles
Retroviruses

